openPR Logo
Press release

Hepatocellular Carcinoma Drug Sales Overview with Pipeline Analysis and Global Market Forecast 2022

08-10-2017 08:18 AM CET | Health & Medicine

Press release from: Orbis Research

Orbis Research

Orbis Research

Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. Most cases of HCC result either from infection with viral hepatitis (Hepatitis B or C), metabolic toxins such as alcohol or aflatoxin, conditions such as hemochromatosis and alpha-deficiency 1-antitrypsin, or NASH.

Browse the report: http://www.orbisresearch.com/reports/index/global-hepatocellular-carcinoma-drug-sales-nexavar-and-miripla-pipeline-analysis-and-global-market-forecast-2022

As per RNCOS report “Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022” the global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/333577

Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.

As per our research, Nexavar is the only approved targeted drug for the advance hepatocellular carcinoma as of now; with the exception of Miripla approved only in Japan. However, there are molecules in the Phase III clinical development as first-line and second-line treatments, promising to influence the competitive landscape over the next two to three years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America is accounted for the largest share. In addition, Asia-Pacific is projected to be the fastest growing region due to the increasing incidence of chronic disorders, such as cancer, diabetes, hepatitis infections, and others.

Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.

Buy the report@http://www.orbisresearch.com/contact/purchase/333577

Major Points From The Table Of Contents:

Analyst View

Research Methodology

Hepatocellular Carcinoma- An Introduction

Market Dynamics

Global Hepatocellular Carcinoma Drug Market Outlook 2022

Global Hepatocellular Carcinoma Drug Pipeline Analysis

Market Segment by Geography

Company Profiles

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Drug Sales Overview with Pipeline Analysis and Global Market Forecast 2022 here

News-ID: 663026 • Views:

More Releases from Orbis Research

Blood Purification Devices Market 2023-2028 | Top Players Baxter International, Cerus Corporation, Cytosorbents Corporation, Nikkiso Co.Ltd, Asahi Kasei Corporation, Aethlon Medical, Haemonetics, Jafron, B. Braun, Fresenius
Blood Purification Devices Market 2023-2028 | Top Players Baxter International, …
Based on the type segment, the portable equipment segment is expected to hold the largest share in Blood Purification Devices in the year 2028. Professionals that are actively involved in the ongoing purification of blood tend to favour portable equipment. Equipment that is portable enables effective emergency care. Additionally, portable equipment is rather space-efficient and compact, which promotes widespread use throughout the blood-purification process. In a manner similar to how
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Minerals, The Honest Company, Fenty Beauty, Aveda Corporation, Westman Atelier, Victoria Beckham Beauty, Kora Organics, Saie, and True Botanicals
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Mineral …
Clean beauty is described as beauty and personal care products that are made with the safest possible ingredients and have the lowest possible environmental impacts. Clean beauty pertains to products that are safe, non-toxic, and clearly labelled ingredients Also, the ingredients used are cruelty-free and are screened for non-GMO feedstock and residual pesticides. Request a pdf brochure @ https://www.orbisresearch.com/contacts/request-sample/6941781 The Clean Beauty Market is valued at USD 5163.17 Million in 2021 and
Outdoor Power Equipment Market Worth USD 6.49 Bn by 2027 - Industry Trends and S …
The outdoor power equipment generally includes, brush cutters, edger, chain saws, power rakes, and more. Outdoor power equipment is commonly used by end users, such as lawn & plant care providers and landscape service providers, for commercial purposes. The global outdoor power equipment market in 2021 was valued at US$32.22 billion. The market value is projected to reach US$46.49 billion by 2027. Outdoor power equipment (OPE) is an equipment with small
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth Drivers, Key Companies and Future Opprtunities
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth …
The latest research on "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends With Impact Of COVID-19 And Forecast up to 2027" have been added to OrbisResearch.com store. The merchant API market refers to the use of APIs by merchants, or businesses that sell goods and services, to connect their systems and processes with those of other

All 5 Releases


More Releases for Hepatocellular

Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy
Hepatocellular Carcinoma HCC Treatment Market: Global Forecast over 2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Global Clinical Trials Review H2 2017
ReportsWeb.com published “Hepatocellular Carcinoma Global Clinical Trials Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Publisher's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular
Trends in the Hepatocellular Carcinoma HCC Treatment Market 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Market 2024: Opportunity Analysis and Forecasts
"The Latest Research Report OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Hepatocellular Carcinoma Market Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver
Hepatocellular Carcinoma HCC Treatment Market Growth and Forecast 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated